BAYER PLC (WT) - WT2024-05 - DAROLUTAMIDE 300 mg Tablets

GoodsAward procedure without prior publication of a call for competition

Awarded value£279,300published contract · exc. VAT

Awarded 16 Aug 2024no call for competition

Awarded to Bayer plc Radiology

What is being bought

Published requirement description

Supply of DAROLUTAMIDE 300 mg Tablets to meet clinical need in the Western Trust for until 15/08/2027.

CPV: Pharmaceutical products

single lot · no lot value published

Lot #1Awarded

Delivery: Northern Ireland

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 23 Aug 2024, 12:09 BST
Last source update: 23 Aug 2024, 12:09 BST
Authority reference: WT2024-05
FTS notice number: 2024/S 000-027039
Classification (CPV): Pharmaceutical products
Delivery area: Northern Ireland (UKN)
Official registry OCID: ocds-h6vhtk-04937f Find a Tender

Why no open competition: The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
Published justification: Regulation 32(2)(b)iii permits the award of a public contract by a negotiated procedure without prior publication where the works, supplies or services can only be supplied by a particular economic operator due to the protection of exclusive rights, including intellectual property rights. The absence of competition is not the result of an artificial narrowing down of the parameters of the procurement.
The Western Health and Social Care Trust requires the purchase of DAROLUTAMIDE 300 mg Tablets which are subject to patent protection / Sole MA Holder and consequently no reasonable alternative of substitute exists.

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £279,3001 contract exc. VAT

Bids received 1

Contracts signed 1latest 16 Aug 2024

Awarded to	Value	Date	Status
Bayer plc Radiology	£279,300 †	—	Awarded

Contracts

BAYER PLC (WT) - WT2024-05 - DAROLUTAMIDE 300 mg Tablets · Bayer plc Radiology
Signed
16 Aug 2024
Value
£279,300
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authorityCentral GovernmentBody governed by public lawHealth Londonderry, Northern IrelandContact name, email, phone

1 commercial party on the notice

BAYER PUBLIC LIMITED COMPANYAwarded supplierGB-COH: 00935048 400 South Oak Way, Reading, Berkshire, England, Reading, South East, RG2 6AD

Official links; attachments are not copied

No document links were published on the notice.